Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
**RNU6-503P** is a **pseudogene** derived from U6 small nuclear RNA (snRNA), a highly conserved noncoding RNA that participates in mRNA splicing as part of the spliceosome[5]. Pseudogenes are generally considered “dead genomic elements” lacking protein-coding capacity or defined biological activity, although a minority (<5%) show signs of transcriptional or regulatory activity[2][6]. U6 snRNA is normally crucial to nuclear pre-mRNA splicing, but copies such as RNU6-503P are typically inactive remnants in the human genome and do not encode functional RNAs or proteins. **Key insights:** - **RNU6-503P** is a non-functional copy of a gene and is not a receptor or enzyme; it is not considered a therapeutic target[2][5]. - Occasional pseudogene transcription occurs, but RNU6-503P does not have documented biological function or disease association in available literature[2][5]. - U6 snRNA pseudogenes are common in vertebrate genomes, likely reflecting the evolutionary importance and prevalence of U6-related elements[5]. - Misclassification can occur in some gene annotation pipelines, but current evidence supports RNU6-503P as an authentic pseudogene rather than a functional gene or therapeutic target[4]. **Summary notes:** - **Not a receptor, enzyme, transporter, or recognized therapeutic target.** - **May be listed in genome annotation databases, but lacks function and clinical relevance.** - **Marked as “incorrect” as a therapeutic target due to its pseudogene status.**
None (no drugs target this pseudogene)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on U6 small nuclear RNA 503, pseudogene (RNU6-503P).